Highlights

  • ResMed Inc. (ASX:RMD) reported approximately USD 1.4 billion of FY27 first-quarter revenue.
  • First-quarter Revenue increased 6%, or 7% in core constant currency.
  • GAAP gross Margin reached 61.5% for the quarter.
  • ResMed maintained FY27 reported revenue guidance of USD 5.75–5.85 billion.

ResMed Inc. supplies sleep and breathing health devices, masks and residential care software to healthcare customers worldwide. During the November 17, 2026 session, shares (ASX:RMD) traded at AUD 35.56, up 1.02%. The October FY27 first-quarter results reported growth in sleep products while management retained its full-year revenue guidance.

Sleep, Breathing and Care Software Businesses

ResMed develops connected medical devices, masks and related products for sleep apnoea and other breathing conditions. It also supplies software used in residential and related care settings. The Business reports Sleep and Breathing Health activities separately from Residential Care Software, allowing device sales and software revenue to be assessed under their different operating characteristics.

October 2026 Trading Update

ResMed's October 29, 2026 announcement covered the first quarter of FY27. The company said revenue was approximately USD 1.4 billion, up 6% on a reported basis and 7% in core constant currency. Management attributed the increase primarily to Demand across sleep devices, masks and accessories, without separating the contribution of every individual product.

On a core constant-currency basis, Americas Sleep and Breathing Health revenue increased 7%, while the corresponding Rest of World business grew 8%. Residential Care Software revenue increased 5%. These measures indicate variations across geographic and product lines. ResMed Inc. (ASX:RMD) also reported a sale of MatrixCare, which should be considered when interpreting reported and core measures.

Quarterly Profitability and Cash Flow

First-quarter GAAP gross margin was 61.5%, while non-GAAP gross margin stood at 62.5%, representing an increase of 50 basis points. GAAP Operating Margin was 32.0% and GAAP Diluted Earnings per Share reached USD 2.92. Non-GAAP operating margin was 35.8%, and non-GAAP diluted EPS was USD 2.91, an increase of 14% compared with the corresponding period.

Operating Cash Flow totalled USD 422 million and free cash flow was USD 374 million. The company stated that cash flow and proceeds from the MatrixCare sale supported approximately USD 1.0 billion of dividends and share repurchases while it continued to invest in product development. Those returns should be assessed alongside the effects of business disposals and continuing operating cash generation.

FY27 Guidance and Operating Priorities

The October announcement maintained reported FY27 revenue guidance of USD 5.75 billion to USD 5.85 billion and core constant-currency revenue growth guidance of 5% to 7%. Non-GAAP diluted earnings per share guidance remained USD 12.00 to USD 12.25. These are management's stated expectations rather than completed outcomes.

The company declared a quarterly Dividend of USD 0.66 per New York Stock Exchange common share, payable in December 2026. ASX-listed Chess Depositary Interests have a ten-to-one ratio to ordinary shares, and their equivalent payment is calculated in Australian currency. For ResMed Inc. (ASX:RMD), future reporting should clarify margins, Operating Cash Flow and growth across the continuing businesses.

Risks and What to Monitor

Medical device demand depends on diagnosis, reimbursement, channel distribution and ongoing product use. Manufacturing expenses, currencies and competition may influence profitability, while connected products and software have privacy, security and service requirements. Changes to the business portfolio can also make year-on-year comparisons more complex.

Subsequent FY27 results can be assessed against the maintained revenue and earnings-per-share ranges. Device volumes, masks and accessories, Residential Care Software, margins and cash conversion remain useful operating indicators for ResMed Inc. (ASX:RMD).

Key Insights

ResMed's first-quarter release showed higher revenue, positive operating cash flow and unchanged FY27 guidance. Reported and adjusted measures provide different views of profitability. Future quarters will establish how continuing product demand, margins and the post-disposal portfolio develop against the company's expectations.